Unknown PHASE4 INTERVENTIONAL 3-arm NCT00813891

Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions Macular Degeneration Visual Acuity

Interventions Ranibizumab

Updated 6 times since 2017 Last updated: Dec 22, 2008 Started: Jan 31, 2009 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Macular Degeneration and Visual Acuity and is currently ongoing. McGill University Health Centre/Research Institute of the McGill University Health Centre leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Oct 2019 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Oct 2019 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Data source: McGill University Health Centre/Research Institute of the McGill University Health Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada